Clinical Trial

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2023-03-23; most recent amendment 2026-06-08.
Status change: Recruiting → Active, Not Recruiting 2025-09-29
Status change: Not Yet Recruiting → Recruiting 2023-12-22
Trial Details
NCT Number NCT05798663
Lead Sponsor Alliance Foundation Trials, LLC.
Collaborators: Genentech, Inc.
Conditions NSCLC
Enrollment 178 participants
Start Date 2023-12-07
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-09